Bamberger D M, Peterson L R, Gerding D N, Moody J A, Fasching C E
J Antimicrob Chemother. 1986 Jul;18(1):51-63. doi: 10.1093/jac/18.1.51.
Ciprofloxacin, azlocillin, ceftizoxime, and amikacin were studied alone and in combination against six Enterobacteriaceae and six strains of Pseudomonas aeruginosa in an infected chamber model in rabbits simulating a closed space infection. In-vivo results were compared with in-vitro tests of inhibition, killing and synergy. Ciprofloxacin was the most effective single agent, with efficacy against five of the six Enterobacteriaceae when used in low doses, and two of the six pseudomonads when used in high doses. The development of in-vitro resistance to ciprofloxacin was observed during therapy in strains which failed to be eradicated. Ciprofloxacin and azlocillin together was the most effective regimen, with efficacy against eleven of the twelve strains. Synergy, as determined by chequerboard testing, did not correlate with in-vivo outcome. Unlike mezlocillin, azlocillin, ceftizoxime or amikacin, MIC testing of ciprofloxacin was predictive of in-vivo success.
在模拟封闭空间感染的兔感染腔模型中，对环丙沙星、阿洛西林、头孢唑肟和阿米卡星单独及联合使用针对六种肠杆菌科细菌和六种铜绿假单胞菌菌株进行了研究。将体内结果与抑制、杀灭和协同作用的体外试验进行了比较。环丙沙星是最有效的单一药物，低剂量使用时对六种肠杆菌科细菌中的五种有效，高剂量使用时对六种假单胞菌中的两种有效。在治疗过程中，未被根除的菌株出现了对环丙沙星的体外耐药性。环丙沙星和阿洛西林联合使用是最有效的治疗方案，对十二种菌株中的十一种有效。通过棋盘试验确定的协同作用与体内结果不相关。与美洛西林、阿洛西林、头孢唑肟或阿米卡星不同，环丙沙星的MIC试验可预测体内治疗成功。
